Brief: Kymera Therapeutics Announces Late-Breaking Oral Presentations On KT-621, A First-In-Class, Oral Stat6 Degrader, At The European Academy Of Dermatology & Venereology And European Respiratory Society Congresses
17/09/2025 14:13
Kymera Therapeutics Inc KYMR.O: KYMERA THERAPEUTICS ANNOUNCES LATE-BREAKING ORAL PRESENTATIONS ON KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER, AT THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY AND EUROPEAN RESPIRATORY SOCIETY CONGRESSES Source text: ID:nGNX6Xm5p Further company coverage: KYMR.O
Recent news on Kymera Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Brief: Kymera Therapeutics Q2 EPS USD -0.62
Brief: Kymera Therapeutics Appoints Terence Rooney, MD, As Chief Medical Officer